Article

Optimization of AAV process development: transfection matters

FectoVIR-AAV 120-100

Home > Blog > Article

Article

FectoVIR-AAV 120-100

Optimization of AAV process development: transfection matters

26/01/2021 (2 months)

in vivo-jetRNA packaging 2020

Promising non-viral vector for efficient and versatile delivery of mRNA for antigen-specific immunotherapy

11/01/2021 (3 months)

gene therapy

Viral vectors for gene therapy in a nutshell: AAVs, lentivirus, adenovirus and retrovirus

10/11/2020 (5 months)

Antibody

Expression of recombinant proteins

27/10/2020 (5 months)

Residual PEIpro test poster

GMP compliant residual PEIpro^® test: one step closer to commercialization

20/10/2020 (5 months)

transfection for vaccines

Transfection toolbox for spike protein vaccine strategies

03/06/2020 (10 months)

Canva - Pills on Gray Background

Solving the viral vector bottleneck during a pandemic

21/04/2020 (12 months)

FectoVIR-AAV 120-100

FectoVIR^®-AAV, a giant step for AAV large scale manufacturing

17/04/2020 (1 year)

in vivo-jetPEI range

in vivo-jetPEI^® Product Range

07/09/2019 (1 year)

lab scientists

Supporting Bladder Cancer Gene Therapy

21/05/2019 (1 year)

in vivo delivery

Non-Viral Vector Mediated Gene Delivery

06/03/2019 (2 years)

PEIpro product range packaging 2020

PEIpro^® Product range

14/12/2018 (2 years)

Give your feedback!